In an article from 340B Report which states that AbbVie will expand its contract pharmacy restrictions with new claims data reporting requirements for 340B grantee covered entities beginning Jan.1. ACH’s Stephanie Krenrich, senior vice president of policy & government affairs, said ACH recognizes the need for compliance with the 340B statute and is advocating for policy proposals that would increase accountability and transparency for covered entities.

“However, it is the role of government regulators, not private-sector pharmaceutical manufacturers, to adjudicate compliance with a federal program. AbbVie joins the ever-growing list of pharmaceutical manufacturers who pile on onerous reporting requirements in an attempt to unlawfully narrow a program that exists solely to support care for the underserved,” Krenrich added in a statement to 340B Report.

Read the article in 340B Report